Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Humacyte Inc (NQ: HUMA )

5.422 +0.722 (+15.36%)
Streaming Delayed Price Updated: 12:54 PM EDT, May 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Humacyte Inc

Humacyte to Present at the Piper Sandler 35th Annual Healthcare Conference
From Humacyte, Inc
Via GlobeNewswire
Humacyte Announces Two Presentations at the VEITHsymposium® of Positive Clinical Results of the Human Acellular Vessel™ (HAV™) in the Treatment of Vascular Trauma
From Humacyte, Inc
Via GlobeNewswire
Sidoti Events, LLC’s Virtual November Micro-Cap Conference
Via ACCESSWIRE
Humacyte Third Quarter 2023 Financial Results and Business Update
From Humacyte, Inc
Via GlobeNewswire
Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 9, 2023
From Humacyte, Inc
Via GlobeNewswire
Humacyte Publishes Preclinical Results Showing Human Acellular Vessel™ (HAV™) Patency as Modified Blalock–Taussig–Thomas Shunt in Juvenile Primate Model
-Outcomes exhibit potential of HAV for palliative treatment of congenital heart disease- 
From Humacyte, Inc
Via GlobeNewswire
Humacyte to Present at the Cantor Global Healthcare Conference
From Humacyte, Inc
Via GlobeNewswire
Humacyte to Host In-Person KOL Event at the New York EDITION on September 20, 2023
From Humacyte, Inc
Via GlobeNewswire
Humacyte Announces Positive Top Line Results from Phase 2/3 Trial of Human Acellular Vessel™ (HAV™) in Treatment of Patients with Vascular Trauma
From Humacyte, Inc
Via GlobeNewswire
Humacyte to Announce Top Line Data from Phase 2/3 V005 Trial in Vascular Trauma Evaluating its Human Acellular Vessel™ (HAV™) Tuesday, September 12, 2023 at 8:00 AM ET
Virtual Webinar to Include Key Opinion Leader Perspectives on the Potential of the HAV in Vascular Trauma Repair 
From Humacyte, Inc
Via GlobeNewswire
Results From Mayo Clinic Clinical Study of Humacyte’s Human Acellular Vessel™ (HAV™) in Treatment of Patients with Chronic Limb Ischemia Presented at Midwestern Vascular Conference
-Researchers concluded that in the clinical study the HAV was a safe, resilient, and effective conduit for arterial bypass and limb salvage- 
From Humacyte, Inc
Via GlobeNewswire
Humacyte Second Quarter 2023 Financial Results and Business Update
From Humacyte, Inc
Via GlobeNewswire
Humacyte Announces Fourth Quarter and Year End 2022 Financial Results and Business Update
From Humacyte, Inc
Via GlobeNewswire
Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 24, 2023
From Humacyte, Inc
Via GlobeNewswire
Humacyte to Present at Upcoming Investor Conferences in March
From Humacyte, Inc
Via GlobeNewswire
Humacyte Publication in the Journal of Vascular Surgery – Vascular Science Reports the Human Acellular Vessel™ (HAV™) Remains Durable at Six Years in Patients with Peripheral Artery Disease
From Humacyte, Inc
Via GlobeNewswire
Humacyte Hosting Key Opinion Leader Webinar on Vascular Trauma: Ukrainian Surgeons Discuss Use of Human Acellular Vessels™ (HAV™) in Wartime
Thursday, December 15, 2022 @ 8:00 AM ET 
From Humacyte, Inc
Via GlobeNewswire
Sidoti's December Small-Cap Virtual Conference
Via ACCESSWIRE
Humacyte Human Acellular Vessel™ (HAV™) Ukraine Humanitarian Results to be Presented at Multiple Vascular Conferences in December 2022
Ukrainian surgeon collaborators will present at the VI Congress of Vascular Surgeons, Phlebologists, and Angiologists of Ukraine and the 11th Munich Vascular Conference 
From Humacyte, Inc
Via GlobeNewswire
Humacyte to Present at the 34th Annual Piper Sandler Healthcare Conference
From Humacyte, Inc
Via GlobeNewswire
Humacyte Third Quarter 2022 Financial Results and Business Update
From Humacyte, Inc
Via GlobeNewswire
Humacyte Presents Six-Month Human Acellular Vessel™ (HAV™) Coronary Artery Bypass Graft (CABG) Data at the American Heart Association Scientific Sessions 2022 Meeting
From Humacyte, Inc
Via GlobeNewswire
Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 10, 2022
From Humacyte, Inc
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.